Literature DB >> 17729111

Catalase deficiency may complicate urate oxidase (rasburicase) therapy.

László Góth1, N William Bigler.   

Abstract

Patients with low (inherited and acquired) catalase activities who are treated with infusion of uric acid oxidase because they are at risk of tumour lysis syndrome may experience very high concentrations of hydrogen peroxide. They may suffer from methemoglobinaemia and haemolytic anaemia which may be attributed either to deficiency of glucose-6-phosphate dehydrogenase or to other unknown circumstances. Data have not been reported from catalase deficient patients who were treated with uric acid oxidase. It may be hypothesized that their decreased blood catalase could lead to the increased concentration of hydrogen peroxide which may cause haemolysis and formation of methemoglobin. Blood catalase activity should be measured for patients at risk of tumour lysis syndrome prior to uric acid oxidase treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17729111     DOI: 10.1080/10715760701482451

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  6 in total

1.  Distinct mechanisms for rasburicase induced hemolytic anemia and methemoglobinemia in tumor lysis syndrome.

Authors:  Rodrigo Lopes da Silva
Journal:  Int J Clin Pharm       Date:  2011-04-26

2.  Catalase -262C>T polymorphisms in Hungarian vitiligo patients and in controls: further acatalasemia mutations in Hungary.

Authors:  Zsuzsanna Kósa; Zsolt Fejes; Teréz Nagy; Melinda Csordás; Enikő Simics; Eva Remenyik; László Góth
Journal:  Mol Biol Rep       Date:  2011-09-24       Impact factor: 2.316

Review 3.  Gout. Novel therapies for treatment of gout and hyperuricemia.

Authors:  Robert Terkeltaub
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

4.  New advances in the treatment of gout: review of pegloticase.

Authors:  Mattheus K Reinders; Tim L Th A Jansen
Journal:  Ther Clin Risk Manag       Date:  2010-10-27       Impact factor: 2.423

Review 5.  PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

Authors:  Ellen M McDonagh; Caroline F Thorn; John T Callaghan; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-09       Impact factor: 2.089

Review 6.  Markers of Oxidative Stress during Diabetes Mellitus.

Authors:  Brahm Kumar Tiwari; Kanti Bhooshan Pandey; A B Abidi; Syed Ibrahim Rizvi
Journal:  J Biomark       Date:  2013-12-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.